- Johnson & Johnson (NYSE:JNJ) is beginning the process of seeking a buyer for its Cordis unit that makes medical devices including stents and catheters, WSJ reports.
- Cordis reportedly could fetch $1.5B-$2B and is expected to attract interest from P-E firms and other health care companies.
- A sale would mark the latest divestiture for JNJ, which is looking to shed slower-growth businesses and reduce annual costs by $1B; JNJ said in 2011 it would leave the cardiac stent business after years of falling sales and market share.
From other sites
at Investopedia (Apr 10, 2015)
at 4-traders.com (Mar 24, 2015)
at Nasdaq.com (Mar 16, 2015)
at Nasdaq.com (Mar 11, 2015)
at Benzinga.com (Feb 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs